Kyverna Therapeutics reports positive 1-year KYSA-8 trial data for miv-cel in stiff person syndrome
KYTX•Kyverna Therapeutics reported positive one-year KYSA-8 trial data for miv-cel in stiff person syndrome, citing sustained clinical benefit and a well-tolerated safety profile. The company said it is working to complete a BLA in its initial indication this quarter.
1. Trial data and filing
Kyverna said it will present the one-year KYSA-8 registrational trial results at MSToronto2026 on Oct. 21, 2026. Updated Phase 1 investigator-initiated findings for miv-cel in progressive multiple sclerosis, showing encouraging early activity, are scheduled for presentation on Oct. 23. Management said it is working to complete a BLA in its initial indication this quarter.
